{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:31:41Z","timestamp":1777253501740,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002241","name":"PRESTO, Japan Science and Technology Agency","doi-asserted-by":"crossref","award":["JPMJPR23R7"],"award-info":[{"award-number":["JPMJPR23R7"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13039-6","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:44:29Z","timestamp":1773413069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines"],"prefix":"10.1186","volume":"26","author":[{"given":"Hiroki","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Inada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Miike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uiri","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuro","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Kurisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mugen","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Jindai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoaki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"10479","key":"13039_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0140-6736(25)00210-7","volume":"405","author":"V Moorthy","year":"2025","unstructured":"Moorthy V, Farrar J. Identifying key randomised clinical trials that could transform clinical care and public health. Lancet. 2025;405(10479):607\u201308. https:\/\/doi.org\/10.1016\/s0140-6736(25)00210-7. [published Online First: 20250213].","journal-title":"Lancet"},{"key":"13039_CR2","unstructured":"WHO. Guidance for best practices for clinical trials. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240097711"},{"key":"13039_CR3","unstructured":"WHO. WHA75. 8 Strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination 2022 [Available from: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA75-REC1\/A75_REC1_Interactive_en.pdf#page=1 accessed June 23 2024."},{"issue":"10422","key":"13039_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(23)02798-8","volume":"403","author":"V Moorthy","year":"2024","unstructured":"Moorthy V, Abubakar I, Qadri F, et al. The future of the global clinical trial ecosystem: a vision from the first WHO global clinical trials forum. Lancet. 2024;403(10422):124\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(23)02798-8.","journal-title":"Lancet"},{"key":"13039_CR5","unstructured":"WHO. Global action plan for clinical trial ecosystem strengthening. 2025. https:\/\/www.who.int\/publications\/i\/item\/B09338"},{"key":"13039_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/d41573-021-00037-3","volume":"20","author":"KW Bugin","year":"2021","unstructured":"Bugin KW. Janet. Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov. 2021;20:254\u201355. https:\/\/doi.org\/10.1038\/d41573-021-00037-3.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"13039_CR7","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1111\/all.14409","volume":"75","author":"S Bonini","year":"2020","unstructured":"Bonini S, Maltese G. COVID-19 Clinical trials: Quality matters more than quantity. Allergy. 2020;75(10):2542\u201347. https:\/\/doi.org\/10.1111\/all.14409.","journal-title":"Allergy"},{"key":"13039_CR8","doi-asserted-by":"publisher","first-page":"106239","DOI":"10.1016\/j.cct.2020.106239","volume":"101","author":"A Dillman","year":"2021","unstructured":"Dillman A, Park JJH, Zoratti MJ, et al. Reporting and design of randomized controlled trials for COVID-19: A systematic review. Contemp Clin Trials. 2021;101:106239. https:\/\/doi.org\/10.1016\/j.cct.2020.106239.","journal-title":"Contemp Clin Trials"},{"key":"13039_CR9","doi-asserted-by":"publisher","first-page":"m1847","DOI":"10.1136\/bmj.m1847","volume":"369","author":"PP Glasziou","year":"2020","unstructured":"Glasziou PP, Sanders S, Hoffmann T. Waste in covid-19 research. BMJ. 2020;369:m1847. https:\/\/doi.org\/10.1136\/bmj.m1847.","journal-title":"BMJ"},{"key":"13039_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jclinepi.2021.06.027","volume":"139","author":"D Wang","year":"2021","unstructured":"Wang D, Chen L, Wang L, et al. Abstracts for reports of randomized trials of COVID-19 interventions had low quality and high spin. J Clin Epidemiol. 2021;139:107\u201320. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.06.027.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"13039_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/s41591-020-1077-z","volume":"26","author":"KAO Tikkinen","year":"2020","unstructured":"Tikkinen KAO, Malekzadeh R, Schlegel M, et al. COVID-19 clinical trials: learning from exceptions in the research chaos. Nat Med. 2020;26(11):1671\u201372. https:\/\/doi.org\/10.1038\/s41591-020-1077-z.","journal-title":"Nat Med"},{"key":"13039_CR12","unstructured":"NIH. COVID treatment developed in the NHS saves a million lives 2021 [Available from: https:\/\/www.england.nhs.uk\/2021\/03\/covid-treatment-developed-in-the-nhs-saves-a-million-lives\/ accessed June 26 2024."},{"key":"13039_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.12688\/wellcomeopenres.19305.1","volume":"9","author":"P Glasziou","year":"2024","unstructured":"Glasziou P, Sanders S, Byambasuren O, et al. Clinical trials and their impact on policy during COVID-19: a review. Wellcome Open Res. 2024;9:20. https:\/\/doi.org\/10.12688\/wellcomeopenres.19305.1.","journal-title":"Wellcome Open Res"},{"issue":"6","key":"13039_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184.","journal-title":"N Engl J Med"},{"issue":"5","key":"13039_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1473-3099(23)00193-7","volume":"23","author":"H Saito","year":"2023","unstructured":"Saito H. International platform trials: as diseases cross borders, so should trials. Lancet Infect Dis. 2023;23(5):530\u201331. https:\/\/doi.org\/10.1016\/S1473-3099(23)00193-7.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"13039_CR16","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/S1473-3099(21)00705-2","volume":"22","author":"H Goossens","year":"2022","unstructured":"Goossens H, Derde L, Horby P, et al. The European clinical research response to optimise treatment of patients with COVID-19: Lessons learned, future perspective, and recommendations. Lancet Infect Dis. 2022;22(5):e153\u201358. https:\/\/doi.org\/10.1016\/S1473-3099(21)00705-2.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"13039_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","volume":"17","author":"DC Angus","year":"2020","unstructured":"Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design. Ann Am Thorac Soc. 2020;17(7):879\u201391. https:\/\/doi.org\/10.1513\/AnnalsATS.202003-192SD.","journal-title":"Ann Am Thorac Soc"},{"issue":"15","key":"13039_CR18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMe2114651","volume":"385","author":"E Rubin","year":"2021","unstructured":"Rubin E. Striving for diversity in research studies. N Engl J Med. 2021;385(15):1429\u201330. https:\/\/doi.org\/10.1056\/NEJMe2114651.","journal-title":"N Engl J Med"},{"key":"13039_CR19","doi-asserted-by":"publisher","unstructured":"Inada M, Ichihara N, Saito H. Global landscape of randomized controlled trials responding to the COVID-19 pandemic: a literature review protocol. F1000Research. 2023;12(133). https:\/\/doi.org\/10.12688\/f1000research.129241.1.","DOI":"10.12688\/f1000research.129241.1"},{"key":"13039_CR20","unstructured":"The World Bank. World Bank Country and Lending Groups. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups accessed March 1 2025."},{"key":"13039_CR21","unstructured":"FDA. Decentralized clinical trials for drugs, biological products, and devices, draft guidance 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/decentralized-clinical-trials-drugs-biological-products-and-devices accessed July 14 2024."},{"key":"13039_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2019.05.009","volume":"113","author":"AC Tan","year":"2019","unstructured":"Tan AC, Jiang I, Askie L, et al. Prevalence of trial registration varies by study characteristics and risk of bias. J Clin Epidemiol. 2019;113:64\u201374. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.05.009.","journal-title":"J Clin Epidemiol"},{"issue":"0 1","key":"13039_CR23","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1097\/qai.0000000000000037","volume":"65","author":"P Ndebele","year":"2014","unstructured":"Ndebele P, Blanchard-Horan C, Shahkolahi A, et al. Regulatory challenges associated with conducting multicountry clinical trials in resource-limited settings. J Acquir Immune Defic Syndr. 2014;65(0 1):S29\u201331. https:\/\/doi.org\/10.1097\/qai.0000000000000037.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"13039_CR24","doi-asserted-by":"publisher","first-page":"e097611","DOI":"10.1136\/bmjopen-2024-097611","volume":"15","author":"S Horii","year":"2025","unstructured":"Horii S, Saito H, Shibata T, et al. Principal investigators\u2019 experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study. BMJ Open. 2025;15(6):e097611. https:\/\/doi.org\/10.1136\/bmjopen-2024-097611.","journal-title":"BMJ Open"},{"issue":"2","key":"13039_CR25","doi-asserted-by":"publisher","first-page":"e220444","DOI":"10.1001\/jamanetworkopen.2022.0444","volume":"5","author":"M Ramanan","year":"2022","unstructured":"Ramanan M, Tong SYC, Kumar A, et al. Geographical representation of low- and middle-income countries in randomized clinical trials for COVID-19. JAMA Netw Open. 2022;5(2):e220444. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0444.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"13039_CR26","doi-asserted-by":"publisher","first-page":"e008012","DOI":"10.1136\/bmjgh-2021-008012","volume":"7","author":"J Miller","year":"2022","unstructured":"Miller J, Millum J. Ethical considerations in international clinical trial site selection. BMJ Glob Health. 2022;7(4):e008012. https:\/\/doi.org\/10.1136\/bmjgh-2021-008012.","journal-title":"BMJ Glob Health"},{"issue":"1","key":"13039_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12939-018-0748-6","volume":"17","author":"C Alemayehu","year":"2018","unstructured":"Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries- a systematic review. Int J Equity Health. 2018;17(1):37. https:\/\/doi.org\/10.1186\/s12939-018-0748-6.","journal-title":"Int J Equity Health"},{"issue":"1","key":"13039_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13063-022-06311-y","volume":"23","author":"S Driver","year":"2022","unstructured":"Driver S, Gray S, Sikhondze W, et al. The European & developing countries clinical trials partnership (EDCTP) knowledge hub: Developing an open platform for facilitating high-quality clinical research. Trials. 2022;23(1):374. https:\/\/doi.org\/10.1186\/s13063-022-06311-y.","journal-title":"Trials"},{"issue":"5","key":"13039_CR29","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/s2214-109x(20)30542-8","volume":"9","author":"JJH Park","year":"2021","unstructured":"Park JJH, Mogg R, Smith GE, et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health. 2021;9(5):e711\u201320. https:\/\/doi.org\/10.1016\/s2214-109x(20)30542-8.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"13039_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J, Pragmatic Trials. N Engl J Med. 2016;375(5):454\u201363. https:\/\/doi.org\/10.1056\/NEJMra1510059.","journal-title":"N Engl J Med"},{"key":"13039_CR31","doi-asserted-by":"publisher","unstructured":"Saito H, Jindai K, Shibata T et al. How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings. Global Health & Medicine 2025;advpub https:\/\/doi.org\/10.35772\/ghm.2024.01082.","DOI":"10.35772\/ghm.2024.01082"},{"issue":"5","key":"13039_CR32","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1016\/s2214-109x(20)30539-8","volume":"9","author":"JJH Park","year":"2021","unstructured":"Park JJH, Grais RF, Taljaard M, et al. Urgently seeking efficiency and sustainability of clinical trials in global health. Lancet Glob Health. 2021;9(5):e681\u201390. https:\/\/doi.org\/10.1016\/s2214-109x(20)30539-8.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"13039_CR33","doi-asserted-by":"publisher","first-page":"e243109","DOI":"10.1001\/jamanetworkopen.2024.3109","volume":"7","author":"A Griessbach","year":"2024","unstructured":"Griessbach A, Sch\u00f6nenberger CM, Taji Heravi A, et al. Characteristics, progression, and output of randomized platform trials: A systematic review. JAMA Netw Open. 2024;7(3):e243109. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.3109.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"13039_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s13063-022-06680-4","volume":"23","author":"SB Love","year":"2022","unstructured":"Love SB, Cafferty F, Snowdon C, et al. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials. 2022;23(1):757. https:\/\/doi.org\/10.1186\/s13063-022-06680-4.","journal-title":"Trials"},{"issue":"7","key":"13039_CR35","doi-asserted-by":"publisher","first-page":"e2221140","DOI":"10.1001\/jamanetworkopen.2022.21140","volume":"5","author":"JJH Park","year":"2022","unstructured":"Park JJH, Sharif B, Harari O, et al. Economic evaluation of cost and time required for a platform trial vs conventional trials. JAMA Netw Open. 2022;5(7):e2221140. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.21140.","journal-title":"JAMA Netw Open"},{"issue":"24","key":"13039_CR36","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1001\/jama.2020.8920","volume":"323","author":"FS Collins","year":"2020","unstructured":"Collins FS, Stoffels P. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): An unprecedented partnership for unprecedented times. JAMA. 2020;323(24):2455\u201357. https:\/\/doi.org\/10.1001\/jama.2020.8920.","journal-title":"JAMA"},{"issue":"9","key":"13039_CR37","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.7326\/m21-1269","volume":"174","author":"L LaVange","year":"2021","unstructured":"LaVange L, Adam SJ, Currier JS, et al. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): designing master protocols for evaluation of candidate COVID-19 therapeutics. Ann Intern Med. 2021;174(9):1293\u2013300. https:\/\/doi.org\/10.7326\/m21-1269.","journal-title":"Ann Intern Med"},{"issue":"9","key":"13039_CR38","doi-asserted-by":"publisher","first-page":"e075903","DOI":"10.1136\/bmjopen-2023-075903","volume":"13","author":"EI Nebie","year":"2023","unstructured":"Nebie EI, Sawadogo HN, van Eeuwijk P, et al. Opportunities and challenges for decentralised clinical trials in sub-Saharan Africa: A qualitative study. BMJ Open. 2023;13(9):e075903. https:\/\/doi.org\/10.1136\/bmjopen-2023-075903.","journal-title":"BMJ Open"},{"issue":"9","key":"13039_CR39","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41591-020-0999-9","volume":"26","author":"R van der Graaf","year":"2020","unstructured":"van der Graaf R, Hoogerwerf MA-O, de Vries MC. The ethics of deferred consent in times of pandemics. Nat Med. 2020;26(9):1328\u201330. https:\/\/doi.org\/10.1038\/s41591-020-0999-9.","journal-title":"Nat Med"},{"key":"13039_CR40","doi-asserted-by":"publisher","unstructured":"Oyama Y, Saito H, Hoshina Y, Ichihara N, Jindai K. What did trial participants in REMAP-CAP Japan experience during the COVID-19 pandemic? A qualitative study. BMC Med Ethics. 2026. https:\/\/doi.org\/10.1186\/s12910-026-01411-9.","DOI":"10.1186\/s12910-026-01411-9"},{"issue":"6","key":"13039_CR41","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/s2589-7500(20)30086-8","volume":"2","author":"K Thorlund","year":"2020","unstructured":"Thorlund K, Dron L, Park J, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health. 2020;2(6):e286\u201387. https:\/\/doi.org\/10.1016\/s2589-7500(20)30086-8.","journal-title":"Lancet Digit Health"},{"issue":"15","key":"13039_CR42","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2023.1784","volume":"329","author":"H Spungen","year":"2023","unstructured":"Spungen H, Burton J, Schenkel S, Schriger DL. Completeness and Spin of medRxiv Preprint and Associated Published Abstracts of COVID-19 Randomized Clinical Trials. JAMA. 2023;329(15):1310.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13039-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13039-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13039-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:31:51Z","timestamp":1777249911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13039-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13039"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13039-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article of the existing evidence in the literature. Therefore, no ethics approval was sought for. The study protocol is publicly available (doi:\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentation"}},{"value":"MI was employed at Novo Nordisk A\/S, Denmark, from 2022 to 2023, and is currently employed at AstraZeneca, Japan.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"834"}}